A detailed history of Jane Street Group, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 44,119 shares of ABUS stock, worth $139,416. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,119
Previous 96,509 54.29%
Holding current value
$139,416
Previous $241,000 53.11%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $118,401 - $152,978
-52,390 Reduced 54.29%
44,119 $113,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $163,100 - $245,132
96,509 New
96,509 $241,000
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $66,324 - $92,200
29,742 Added 27.91%
136,288 $412,000
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $167,463 - $249,879
87,677 Added 464.66%
106,546 $248,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $44,616 - $68,348
-23,732 Reduced 55.71%
18,869 $36,000
Q2 2022

Aug 16, 2022

SELL
$1.98 - $3.17 $77,641 - $124,305
-39,213 Reduced 47.93%
42,601 $115,000
Q1 2022

May 17, 2022

SELL
$2.42 - $3.98 $655,979 - $1.08 Million
-271,066 Reduced 76.82%
81,814 $244,000
Q4 2021

Feb 15, 2022

BUY
$3.11 - $4.61 $404,670 - $599,848
130,119 Added 58.41%
352,880 $1.37 Million
Q3 2021

Nov 16, 2021

BUY
$2.65 - $4.62 $534,043 - $931,050
201,526 Added 949.03%
222,761 $956,000
Q2 2021

Aug 16, 2021

SELL
$2.5 - $3.51 $80,317 - $112,765
-32,127 Reduced 60.21%
21,235 $65,000
Q1 2021

May 18, 2021

BUY
$3.14 - $4.84 $44,895 - $69,202
14,298 Added 36.6%
53,362 $177,000
Q4 2020

Feb 17, 2021

BUY
$2.76 - $4.97 $61,379 - $110,527
22,239 Added 132.18%
39,064 $139,000
Q3 2020

Nov 17, 2020

SELL
$1.75 - $6.2 $156,373 - $554,007
-89,356 Reduced 84.15%
16,825 $53,000
Q2 2020

Aug 17, 2020

BUY
$0.91 - $2.36 $30,262 - $78,484
33,256 Added 45.6%
106,181 $194,000
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $73,654 - $249,403
72,925 New
72,925 $73,000
Q3 2019

Nov 14, 2019

SELL
$1.34 - $2.4 $224,031 - $401,251
-167,188 Closed
0 $0
Q2 2019

Aug 15, 2019

BUY
$1.46 - $4.44 $244,094 - $742,314
167,188 New
167,188 $348,000
Q4 2017

Feb 15, 2018

SELL
$4.45 - $7.7 $48,874 - $84,569
-10,983 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $37,342 - $76,881
10,983
10,983 $68,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $474M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.